Fate Therapeutics, Inc.

... ...
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.49%132.330.0%$2558.09m
BNGOBioNano Genomics, Inc. 11.25%9.200.0%$1880.56m
GILDGilead Sciences, Inc. 0.64%67.411.0%$666.95m
AMGNAmgen, Inc. 1.14%254.901.3%$566.31m
CRSPCRISPR Therapeutics AG 1.52%187.910.6%$493.36m
ALXNAlexion Pharmaceuticals, Inc. 1.29%159.902.0%$482.99m
REGNRegeneron Pharmaceuticals, Inc. 1.45%543.242.7%$480.77m
NVAXNovavax, Inc. 1.41%124.1292.9%$434.84m
ILMNIllumina, Inc. 0.66%407.563.5%$396.91m
VRTXVertex Pharmaceuticals, Inc. 0.69%240.291.9%$362.91m
SRPTSarepta Therapeutics, Inc. 0.36%97.2713.8%$357.88m
BIIBBiogen, Inc. 0.02%270.191.7%$326.74m
BNTXBioNTech SE 1.63%107.150.0%$304.43m
EXASEXACT Sciences Corp. 0.57%148.9119.6%$241.24m
PACBPacific Biosciences of California, Inc. 2.73%37.307.4%$237.10m

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.